Arcadia Biosciences (RKDA) Misses Q4 EPS by 97c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts RKDA Hot Sheet
Join SI Premium – FREE
Arcadia Biosciences (NASDAQ: RKDA) reported Q4 EPS of ($0.97). Revenue for the quarter came in at $900 thousand.
For earnings history and earnings-related data on Arcadia Biosciences (RKDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Greggs Plc. (GRG:LN) (GGGSF) to Neutral
- ICICI Prudential Asset Management (ICICIAMC:IN) PT Lowered to INR3,330 at BofA Securities
- Morgan Stanley Downgrades Arch Capital (ACGL) to Equalweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
